Axon Enterprise (NASDAQ:AXON) President Joshua Isner Sells 13,000 Shares of Stock

Axon Enterprise, Inc (NASDAQ:AXON) President Joshua Isner sold 13,000 shares of the stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $488.45, for a total transaction of $6,349,850.00. Following the transaction, the president owned 169,125 shares in the company, valued at approximately $82,609,106.25. This trade represents a 7.14% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Axon Enterprise Stock Down 3.1%

Shares of Axon Enterprise stock opened at $471.06 on Tuesday. The company has a market cap of $37.97 billion, a price-to-earnings ratio of 189.18, a price-to-earnings-growth ratio of 8.84 and a beta of 1.45. The company’s 50 day moving average is $408.45 and its 200 day moving average is $491.12. Axon Enterprise, Inc has a twelve month low of $339.01 and a twelve month high of $885.91. The company has a quick ratio of 1.93, a current ratio of 2.27 and a debt-to-equity ratio of 0.49.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share for the quarter, beating analysts’ consensus estimates of $1.60 by $0.01. The company had revenue of $807.35 million for the quarter, compared to the consensus estimate of $778.91 million. Axon Enterprise had a net margin of 6.90% and a return on equity of 3.78%. The firm’s revenue for the quarter was up 33.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.47 earnings per share. Research analysts anticipate that Axon Enterprise, Inc will post 1.82 EPS for the current year.

Wall Street Analyst Weigh In

AXON has been the topic of several recent research reports. Weiss Ratings upgraded shares of Axon Enterprise from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, May 8th. Citizens Jmp decreased their price target on shares of Axon Enterprise from $825.00 to $700.00 and set a “market outperform” rating on the stock in a research report on Thursday, May 7th. Royal Bank Of Canada decreased their price target on shares of Axon Enterprise from $860.00 to $735.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 25th. Craig Hallum reiterated a “buy” rating and issued a $820.00 price target on shares of Axon Enterprise in a research report on Wednesday, February 25th. Finally, Piper Sandler decreased their price target on shares of Axon Enterprise from $690.00 to $674.00 and set an “overweight” rating on the stock in a research report on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $712.75.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in Axon Enterprise by 0.6% in the fourth quarter. Vanguard Group Inc. now owns 9,367,224 shares of the biotechnology company’s stock worth $5,319,928,000 after acquiring an additional 53,060 shares during the period. Geode Capital Management LLC raised its position in shares of Axon Enterprise by 1.6% during the 4th quarter. Geode Capital Management LLC now owns 2,226,159 shares of the biotechnology company’s stock valued at $1,265,657,000 after purchasing an additional 35,544 shares during the period. Baillie Gifford & Co. raised its position in shares of Axon Enterprise by 1,198.7% during the 4th quarter. Baillie Gifford & Co. now owns 1,642,578 shares of the biotechnology company’s stock valued at $932,869,000 after purchasing an additional 1,516,099 shares during the period. Sands Capital Management LLC raised its position in shares of Axon Enterprise by 11.6% during the 4th quarter. Sands Capital Management LLC now owns 1,609,436 shares of the biotechnology company’s stock valued at $914,047,000 after purchasing an additional 167,095 shares during the period. Finally, Wellington Management Group LLP raised its position in shares of Axon Enterprise by 326.9% during the 4th quarter. Wellington Management Group LLP now owns 1,539,738 shares of the biotechnology company’s stock valued at $874,463,000 after purchasing an additional 1,179,038 shares during the period. 79.08% of the stock is currently owned by institutional investors.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.